# Yingke Capital

> Yingke Capital is a VC fund in Fuzhou backing Health Care and Biotechnology. See 98 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Fuzhou, China
- Total investments: 98
- Last investment: Jul 2026
- Lead investor: 44%
- Last updated: Aug 2026
- Website: http://www.yingkepe.com/

Yingke Capital is a principal investment firm specializing in pre-IPO investments. It seeks to invest in 5G internet of things, biomedical, environmental and facilities services, new energy, consumer upgrade, smart manufacturing and materials sector. Yingke Capital prefers to invest in companies with high technology R&D and productioncapacity. Mingfei Qian founded it in 2010, with its headquarters in Fuzhou in China.

## Contacts

5 contacts available for Yingke Capital. Shizune tracks 7 team members at Yingke Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/yingke-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $425k–$74M |
| Series B | $14M–$412M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 20 | 20% |
| Biotechnology | 18 | 18% |
| Manufacturing | 16 | 16% |
| Medical | 13 | 13% |
| Pharmaceutical | 10 | 10% |

77 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 10 | 10% |
| Funding Round | 10 | 10% |
| Seed | 7 | 7% |
| Series A | 7 | 7% |
| Series C | 7 | 7% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 55 | 56% |
| United States | 4 | 4% |
| Taiwan | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chen Yulei | Chief Investment Officer | 1 | https://shizune.co/investors/profile/chen-yulei-fbff |
| Manying Lai | President | 0 | https://shizune.co/investors/profile/manying-lai |
| Shi Zhengzheng | Partner | 2 | https://shizune.co/investors/profile/shi-zhengzheng |
| Shuqing Wu | President of Financial Division | 0 | https://shizune.co/investors/profile/shuqing-wu |
| Xiaochen Zhou | Vice-President | 0 | https://shizune.co/investors/profile/xiaochen-zhou |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Physen AI | Physen AI is a specialized physical interaction data infrastructure company focused on the embodied intelligence and robotics sector. |  | Angel | Jul 29, 2026 |  |
| Listenai | Listenai is an enterprise that provides AI chips and industry solutions for the field of artificial intelligence and the Internet of Things. | $73.7M | Series B | Jul 10, 2026 |  |
| Vita Dynamics | Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently. | $73.6M | Seed | May 11, 2026 |  |
| Yizhu Technology | Yizhu Technology is a software company that specializes in AI computing power, engineering and consulting for storage data. |  | Venture - Series Unknown | Oct 29, 2025 |  |
| Lingdong General | Lingdong General is a manufacturing company that provides research and development for industrial and service consumer robots. |  | Angel | Aug 12, 2025 |  |
| Lingdong General | Lingdong General is a manufacturing company that provides research and development for industrial and service consumer robots. |  | Seed | Aug 12, 2025 |  |
| Vita Dynamics | Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently. |  | Angel | Aug 07, 2025 |  |
| Junde Pharmaceutical | Junde Medicine is a full-cycle innovator in chronic disease therapeutics. It helps in developing transformative drug-device combination products and new treatment methods by integrating materials science, pharmacy, biology, engineering, machine learning, and other multidisciplinary cutting-edge technologies to create innovative therapies for thefull cycle of chronic diseases. The company focuses on unmet clinical needs for chronic diseases such as obesity, diabetes, mental illness, and metabolic-related fatty liver disease. | $13.7M | Series A | Apr 18, 2025 |  |
| WestGene Biopharma | WestGene Biopharma is a high-tech enterprise that focuses on the research and development, manufacturing and sales of mRNA therapeutics and adjuvants. | $41.8M | Series A | Jun 20, 2023 |  |
| EnCureGen Pharmaceuticals | Huizhengqi Medicine is a pharmaceutical company that develops mRNA drugs for the treatment of tumor and immunity diseases. |  | Seed | Jun 08, 2023 |  |

10 of 98 investments shown.

## Co-investors
- [Shenzhen Capital Group](https://shizune.co/investors/profile/shenzhen-capital-group) — VC Fund, 5 deals together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 4 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 4 deals together
- [YF Capital](https://shizune.co/investors/profile/yf-capital) — VC Fund, 4 deals together
- [CPE](https://shizune.co/investors/profile/citic-pe) — VC Fund, 3 deals together
- [Tigermed](https://shizune.co/investors/profile/hangzhou-tigermed-technology-co-ltd) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Breakthrough Energy Ventures](https://shizune.co/investors/profile/breakthrough-energy-ventures) — VC Fund
- [Shell Ventures](https://shizune.co/investors/profile/shell-technology-ventures) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Energy Investors in China](https://shizune.co/investors/energy-investors-china)
- [Energy VC Funds in China](https://shizune.co/investors/energy-vc-funds-china)
- [Sustainability VC Funds in China](https://shizune.co/investors/sustainability-vc-funds-china)
- [Impact VC Funds in China](https://shizune.co/investors/impact-vc-funds-china)
- [Clean Energy Investors in Asia](https://shizune.co/investors/clean-energy-investors-asia)
- [Clean Energy Investors in China](https://shizune.co/investors/clean-energy-investors-china)

## FAQ

### What does Yingke Capital invest in?

Yingke Capital invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series B and Funding Round stage. Most of the 98 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Yingke Capital's check size?

Yingke Capital typically joins rounds of $425k–$74M at Seed and $14M–$412M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Yingke Capital participates in.

### How do I contact Yingke Capital?

Public channels for Yingke Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Yingke Capital?

The team at Yingke Capital includes Chen Yulei (Chief Investment Officer), Manying Lai (President) and Shi Zhengzheng (Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co